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C ell Surface Receptors and Psoriasis 
For years, says Jonath an Mansbridge of the Psoriasis Research 
InStitute in Stanfo rd , California, there has been a " long and con-
fused literature" discussing w hether the neutrophiJs of psorias is 
patients are the same as o r different from those of people without 
p soriasis. In this issue, Wieslaw Glinski , T odd Anhalt , and Mans-
bridge, of Stanford Uni versity and the Psoriasis Research Insti-
tute, . report on a series of experiments designed to see w hether 
certam cell surface receptors are different on neutrc.phils of pso-
n asls patients. They report that these receptors do behave dif-
ferently, but the difference is not what they expected . . 
The Stanford group started with a well-es tablished observation: 
neutrophils contain receptors on their surface for a hexapeptide, 
N-f~rmyl-Met-Leu-Phe, which is an analog of a po rtion of a 
sp ecifi c bacterial protein . Presumably, these receptors enable the 
neutrophils to recognize bacteria and move toward them 
(chemotaxsis). 
If there are no bacteria around , the neutrophils have only a 
small number o f the peptide receptors on their surfaces, but in 
the presence of bacteria or of the bacterial peptide, the cells produce 
a large number of the receptors on their surfaces. Then the re-
ceptors bind to the peptide and both receptor and peptide enter 
the cell. Finally, the receptors th at entered the cell re-appea r on 
th e cell surface as unoccupied receptors that can now find more 
p e ptide. 
If investigators add a low concentration of the peptide, the 
number of receptors on the cell surfaces increases-a process caIled 
up-regulation. If they add a large amount of peptide, many of 
th e receptors are tied up takin g the peptide into the cells and the 
net number of receptors on the cell surface decreases- a process 
called down- regulation. Finally, researchers can block down-reg-
ulation wi th cytochalasin B, which interferes w ith the cytoskel-
eton of the cell. 
With this armamentarium , the Stanford researchers proceeded 
to ask whether the neutro phils of psoriatic patients are different 
from normal. [n pso riasis, says Mansbridge, " the one clear fac t 
is that there are infiltrates of neutrophils into the skin ." [t has 
been proposed that these neutrophils are unusually sensitive to 
chemotactic substances, which might mean that the cells are more 
able to up- regulate their receptors. 
But Glinski , Anhalt , and M ansbridge found that the neutrophils 
of psorias is patients are less able to up-regulate. When the cells 
were exposed to just the bacterial peptide or when they were also 
exposed to cytochalasin B , they had fewer receptors on their 
surface. 
It is no t entirely clea r why this should be the case. O ne possible 
explanation is that the cells of psoriati c patients are habituated or 
" desani tized" by the constant presence of chemotactic fac tors. 
This, M ansbridge points out, is pure speculation, however, and 
for now, all the group can say for sure is that the neutrophils o f 
pso riatic patients are different from those of normal controls. 
Treating Melanoma Without Surgery 
Heat, delivered superficiaIly to mice with melanomas, is a highly 
effective treatment, reports Norman Levine of the University of 
Arizona Health Sciences Center in Tucson. Levine, who says his 
goal is to use heat to trea t human melanoma, reports his results 
in this issue. 
Levine was led to the experiments w ith mi ce when he consid-
ered the effectiveness o f a device, invented 10 yea rs ago at Los 
Alamos N ational Laboratory, that can deliver radiofrequency heat. 
T h e device is " so small that you can hold it in the palm of your 
hand and it weighs about a pound," Levine says. For this reason, 
it is " very convenient in an outpatient setting. " 
T he device is already being used to treat "cancer eye", a low-
grade squamous cell cancer of cattle. Veterinarians take the device 
to the field where the cattle graze and use it to apply hea t to the 
can cerous eyes. The heat treatment destroys the cancer. 
So Levine, who says he is " interested, in a general way, in 
nonsurgical trea tments for skin cancer," decided to use the device 
in a mouse model of melanoma. It is alread y well kn own that 
malignant cells are more sensitive to heat than normal cells and 
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a number of researchers have tried to trea t tumors by appl ying 
heat. But, says Levine, " nea rly all hyperthermia has been deliv-
ered to deep tumors.'That means you can ' t heat the tumors very 
much." Resea rchers typically heat the deep tumors to at most 
one to two degrees above body temperature-to temperatures 
that are generall y no higher than 43 degrees. H owever, Levine 
notes, "you can deliver much higher temperatures to the skin . " 
Levine therefore implanted melanomas in mice to see if he could 
eradicate them with heat treatments and to see what, if any, are 
the side effects of this treatment. He finds that the melanoma is 
exquisitely sensitive to heat. After 30 seconds of heat treatment, 
there is, he says, "a remarkable clearing of the tumor with min-
imal effects to surroundin g no rmal tissue." He also found that 
he needed to heat the tum or to at least 48 degrees, which is a 
much higher temperatu re than is typicall y achieved when internal 
tumors are heated. Now Levine is experimenting with diffe rent 
regimens-trying lower temperatures but repeated trea tments, 
for example, and testing oth er reagents, such as topical retinoids, 
in addition to heat . So far, his results are very promising. 
